D2NL34 Stock Overview
A biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Denali Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$33.93 |
| 52 Week High | US$36.20 |
| 52 Week Low | US$16.04 |
| Beta | 1.39 |
| 11 Month Change | 12.61% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -9.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| D2NL34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 0.7% |
| 1Y | n/a | 11.5% | -0.7% |
Return vs Industry: Insufficient data to determine how D2NL34 performed against the BR Biotechs industry.
Return vs Market: Insufficient data to determine how D2NL34 performed against the BR Market.
Price Volatility
| D2NL34 volatility | |
|---|---|
| D2NL34 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in BR Market | 8.1% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: D2NL34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine D2NL34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 390 | Ryan Watts | www.denalitherapeutics.com |
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases.
Denali Therapeutics Inc. Fundamentals Summary
| D2NL34 fundamental statistics | |
|---|---|
| Market cap | R$20.45b |
| Earnings (TTM) | -R$2.48b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.2x
P/E RatioIs D2NL34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D2NL34 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$412.36m |
| Gross Profit | -US$412.36m |
| Other Expenses | US$15.14m |
| Earnings | -US$427.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.97 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did D2NL34 perform over the long term?
See historical performance and comparison